146 related articles for article (PubMed ID: 27461360)
21. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
22. Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury.
Ehedego H; Mohs A; Jansen B; Hiththetiya K; Sicinski P; Liedtke C; Trautwein C
Oncogene; 2018 Jun; 37(25):3329-3339. PubMed ID: 29551768
[TBL] [Abstract][Full Text] [Related]
23. Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D; Weir BA; Au-Yeung G; Alsop K; Mitchell G; George J; ; Davis S; D'Andrea AD; Simpson K; Hahn WC; Bowtell DD
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19489-94. PubMed ID: 24218601
[TBL] [Abstract][Full Text] [Related]
24. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
[TBL] [Abstract][Full Text] [Related]
25. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Etemadmoghadam D; deFazio A; Beroukhim R; Mermel C; George J; Getz G; Tothill R; Okamoto A; Raeder MB; Harnett P; Lade S; Akslen LA; Tinker AV; Locandro B; Alsop K; Chiew YE; Traficante N; Fereday S; Johnson D; Fox S; Sellers W; Urashima M; Salvesen HB; Meyerson M; Bowtell D;
Clin Cancer Res; 2009 Feb; 15(4):1417-27. PubMed ID: 19193619
[TBL] [Abstract][Full Text] [Related]
26. Novel therapeutics in low-grade serous ovarian cancer.
Cobb L; Gershenson D
Int J Gynecol Cancer; 2023 Mar; 33(3):377-384. PubMed ID: 36878564
[TBL] [Abstract][Full Text] [Related]
27. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2.
Hayami R; Sato K; Wu W; Nishikawa T; Hiroi J; Ohtani-Kaneko R; Fukuda M; Ohta T
Cancer Res; 2005 Jan; 65(1):6-10. PubMed ID: 15665273
[TBL] [Abstract][Full Text] [Related]
29. Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability.
Jiang W; Huang H; Ding L; Zhu P; Saiyin H; Ji G; Zuo J; Han D; Pan Y; Ding D; Ma X; Zhang Y; Wu J; Yi Q; Liu JO; Huang H; Dang Y; Yu L
Oncogene; 2015 Aug; 34(34):4460-70. PubMed ID: 25399696
[TBL] [Abstract][Full Text] [Related]
30. Cyclin E1 knockdown induces apoptosis in cancer cells.
Gurzov EN; Izquierdo M
Neurol Res; 2006 Jul; 28(5):493-9. PubMed ID: 16808878
[TBL] [Abstract][Full Text] [Related]
31. CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer.
Gorski JW; Ueland FR; Kolesar JM
Diagnostics (Basel); 2020 May; 10(5):. PubMed ID: 32380689
[TBL] [Abstract][Full Text] [Related]
32. The pro-inflammatory effect of obesity on high grade serous ovarian cancer.
Gunderson CC; Ding K; Dvorak J; Moore KN; McMeekin DS; Benbrook DM
Gynecol Oncol; 2016 Oct; 143(1):40-45. PubMed ID: 27423378
[TBL] [Abstract][Full Text] [Related]
33. Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells.
Yan H; Tong J; Lin X; Han Q; Huang H
Mol Med Rep; 2015 Aug; 12(2):1783-8. PubMed ID: 25891642
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
35. Small interference RNA-mediated suppression of overexpressed cyclin E protein restores G1/S regulation in NIH-OVCAR-3 ovarian cancer cells.
Todd MC; Spruill SC; Meerbrey KL
Int J Oncol; 2009 Aug; 35(2):375-80. PubMed ID: 19578752
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of succinate dehydrogenase sensitizes cyclin E-driven ovarian cancer to CDK inhibition.
Guo T; Gu C; Chen X; Kang Y; Li B; Xu C
Biofactors; 2016; 42(2):171-8. PubMed ID: 26826064
[TBL] [Abstract][Full Text] [Related]
37. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
38. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
39. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Sugimoto K; Tai Y; Hando T; Tokuda M
Gynecol Oncol; 2001 Oct; 83(1):56-63. PubMed ID: 11585414
[TBL] [Abstract][Full Text] [Related]
40. CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination.
Brown VE; Moore SL; Chen M; House N; Ramsden P; Wu HJ; Ribich S; Grassian AR; Choi YJ
NAR Cancer; 2023 Sep; 5(3):zcad039. PubMed ID: 37519629
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
